• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Prospects and progress of immunotherapy for bladder cancer
【24h】

Prospects and progress of immunotherapy for bladder cancer

机译：膀胱癌免疫疗法的前景与进展

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: With recent advances in immunooncology and the introduction of checkpoint inhibitors into clinical practice for many cancers, the treatment landscape of urothelial carcinoma has changed dramatically and will continue to change further. Currently, a number of compounds and combinations are under investigation in numerous clinical trials and various clinical scenarios for bladder cancer.Areas covered: In this review, the authors provide an overview of the history and rationale for immunotherapy in bladder cancer. They also provide the currently available data evaluating checkpoint inhibitors for bladder cancer, and discuss ongoing trials and future perspectives for urothelial carcinoma treatment.Expert opinion: The introduction of checkpoint inhibitors into the management of bladder cancer marks a significant milestone for this disease. Checkpoint inhibitors have the potential to impact patients across multiple disease states from non-muscle-invasive disease to metastatic tumors refractory to conventional treatment. That being said, validated biomarkers, including genetic signatures, to accurately predict response, and the establishment of optimal sequencing and combination of these immunotherapeutic agents with chemo/radiotherapy are urgently needed.
机译：介绍：随着免疫科学的最新进展以及将检查点抑制剂引入许多癌症的临床实践中，尿路上皮癌的治疗景观发生了显着变化，并将继续进一步改变。目前，许多化合物和组合都在许多临床试验和膀胱癌的各种临床情景中进行了调查。覆盖着：在本次审查中，作者概述了膀胱癌免疫疗法的历史和理由。他们还提供目前可用的数据评估膀胱癌的检查点抑制剂，并讨论持续的试验和未来的尿路上癌治疗的视角。患者意见：将检查点抑制剂引入膀胱癌的管理标志着这种疾病的重要里程碑。检查点抑制剂具有从非肌肉侵入性疾病到转移治疗的转移肿瘤难以影响患者的患者。所说的是，验证的生物标志物，包括遗传签名，以准确地预测反应，并迫切需要建立与化学/放射治疗的这些免疫治疗剂的最佳测序和组合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号